GAO Oversight Of FDA Performance Included In House Device User Fee Bill
This article was originally published in The Gray Sheet
Executive Summary
FDA's ability to achieve timely review of premarket applications will be closely monitored by Congress and industry if the agency implements a planned medical device user fee program
You may also be interested in...
Device Industry Extols Medicare Passage Despite Competitive Bidding Thorn
AAHomecare plans to meet with CMS officials Dec. 3 to seek clarification on DME competitive bidding provisions in the Medicare reform bill, following whirlwind floor votes and last-minute negotiating
Device Industry Extols Medicare Passage Despite Competitive Bidding Thorn
AAHomecare plans to meet with CMS officials Dec. 3 to seek clarification on DME competitive bidding provisions in the Medicare reform bill, following whirlwind floor votes and last-minute negotiating
Biologics Center 510(k) Reviews Show Improvement In Early Fiscal ’03 – CBER
Increased willingness by Center for Biologics Evaluation & Research reviewers to participate in interactive reviews could help reduce review cycles and times for devices and in vitro diagnostics at the biologics center, attorney Jonathan Kahan suggested